
|Videos|March 12, 2022
Dr. Eric Klein on the “impressive” performance of IsoPSA in recent study
Author(s)Urology Times staff
“I think the take home message is that [IsoPSA is] an easy test to use,” says Eric A. Klein, MD.
Advertisement
In this video, Eric A. Klein, MD, discusses the key takeaways of the recent Urology Practice study “IsoPSA reduces provider recommendations for biopsy and magnetic resonance imaging in men with total prostate specific antigen ≥4 ng/mL: a real-world observational clinical utility study” and also shares what research is coming for the test. Klein is Emeritus Professor and Chair of the Glickman Urological & Kidney Institute at Cleveland Clinic and Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
5










